Закажите звонок

Отправить
×

Спасибо!

Ваша заявка успешно отправлена. В ближайшее время с Вами свяжется наш специалист.
×

List of publications for

×

European Science Review, Issue 9-10/2016

A spectrum of the opportunistic and associated diseases in patients with natural course of the HIV-infection

DOI: https://doi.org/10.29013/ESR-16-9.10-77-79

Pages: 77 - 79

Authors: Musabaeva N. E., Bayjanov A. K.

Abstract: The research has been aimed at studying of a degree of incidence of the opportunistic and associated diseases in patients with natural course of the HIV-infection. Development of a number of opportunistic diseases is the basic indicator of HIV-infection progression. Up to date, there are a number of scientific papers dedicated to studying of the opportunistic infections [1; 2]. Among the HIV-infected patients, tuberculosis [3] is mainly developed infection out of the opportunistic infections, which is one of the basis reasons for patients’ death rate. The risk of tuberculosis reactivation in the HIV-infected patients with positive tuberculine test is 7–10% within a year, and 20–70% of new cases of active tuberculosis in the developing countries. Virus infections (CMV, virus hepatitis С, etc.) [4; 7] also have active influence on the immune system. It is known that the opportunistic diseases under the HIV-infection mutually aggravate the immune system state at the same time facilitating fast transition of the HIV-infection to the end stage of the disease. This is why there is a need to study a spectrum of the opportunistic diseases for the purpose of timely therapy of both the region-specific opportunistic diseases and the HIV-infection [5; 6; 8; 9].

Keywords: opportunistic diseases, chronic virus hepatitis В, С and D, cytomegalovirus infection, tuberculosis, lymphoma, chorioretinitis, pneumocystic pneumonia

Bibliography:
1. Buchacz K. AIDS-defining opportunistic illnesses in US patients, – 1994–2007: A cohort study. AIDS – 2010. Jun 19; 24:1549.
2. Bushman F. D., Nabel G. J., Swanstrom R. HIV: From biology to prevention and treatment. – Cold Spring Harbor, New York, USA:
Cold Spring Harbor Laboratory Press, – 2012. – Р. 321–343.
3. Clark P. M., Karagoz Т., Apikogly-Rabus S., Izzettin F. V. Effect of pharmacist-led patient education on adherence to tuberculosis treatment//
Amer. J. Health-System Pharmacy. – 2007. – Vol. 64, N 5. – P. 497–505.
4. Duerst R. Innate immunity to herpes simplex virus type 2//Viral immunology – 2003 – Vol. 16, № 4 – P. 475–490.
5. Friedrich B. M., Dziuba N., Li G. et. Host factors mediating HIV‑1 replication. Virus Res. – 2011 Nov; 161 (2): 101–14.
6. Hall J. C., Hall B. J., Cockerell C. J. HIV/AIDS in the post-HAART era: Manifestations, treatment, and epidemiology. – Shelton, CT,
USA: People’s Medical Publishing House – USA, – 2011. – Р. 389–403.
7. Joshi D., O’Grady J., Dieterich D. et al. Increasing burden of liver disease in patients with HIV infection. Lancet, – 2011; – 377: 1198–
1209.
8. Lever A. M., Jeang K. T. Insights into cellular factors that requlate HIV‑1 replication in human cells. Biochemistry. – 2011 Feb – 15;
50(6): 920–31.
9. Saag M. S., Chambers H. F., Eliopoulos G. M., Gilbert D. N., Moellering R. C. The Sanford guide to HIV/AIDS therapy – 2012. – Sperryville,
VA, USA: Antimicrobial Therapy Inc., – 2012. – Р. 214.